Add to a list

Inactive Instrument

LOTUS PHARM Stock OTC Bulletin Board

LTUS

US5457151042

Pharmaceuticals

OTC Markets Traded

End-of-day quote OTC Bulletin Board
- ^USD	-

01/08/23	Amarin, Lotus Pharmaceuticals Agree to Exclusive Vazkepa Distribution Deal in 10 Asian Countries	MT
26/11/21	Thai oil firm PTT expands pharma business with $475 million Alvogen deal	RE

Lotus Pharmaceuticals Inc is a company mainly engaged in development, manufacture, and sales of pharmaceuticals. The Company produces crude medicine and drugs in forms of tablets, capsules, granules, eye-drops, and freeze-dried powder injection. The Company's drug development is focused on the treatment of cerebro-cardiovascular disease, asthma, and diabetes. The Company operated in two business segment Wholesales segment and Retail segment. The Company's products include Maixin-valsartan capsules for the treatment of hypertension, Muxineye drops for the treatment of glaucoma and Yipubishan-octreotide Acetate Injection solution for the treatment of gastric ulcers. The Company mainly conducts its businesses in the domestic market and overseas markets.

Employees

Sector

Pharmaceuticals

More about the company

The best tools reserved for subscribers to boost the performance of your investments!

Market Cap	9.74M 8.7M 8.09M 7.36M 13.89M 942M 13.95M 97.35M 38.14M 480M 36.56M 35.76M 1.54B	P/E 2009	3.88x	P/E 2010	4.84x
Enterprise Value	14.38M 12.85M 11.95M 10.87M 20.52M 1.39B 20.61M 144M 56.35M 710M 54.01M 52.83M 2.28B	EV / Sales 2009	1.02x	EV / Sales 2010	0.95x
Free-Float	99%	Yield 2009 *	-	Yield 2010	-

01/08/23	Amarin, Lotus Pharmaceuticals Agree to Exclusive Vazkepa Distribution Deal in 10 Asian Countries	MT
26/11/21	Thai oil firm PTT expands pharma business with $475 million Alvogen deal	RE
28/09/21	Lotus Pharmaceuticals : Temasek-backed Vertex expects at least $400 million in new S.E.Asia/India fund	RE
16/05/12	Lotus Pharmaceuticals, Inc. has Changed its Ticker to LTUS from LTUSE	CI
19/04/12	Lotus Pharmaceuticals, Inc. has Changed its Ticker to LTUS.E from LTUS	CI

31/12	Lotus Pharmaceutical Supports Street Medicine Program to Expand Access to Care for Those Most in Need	AQ
06/10/25	Lotus Enters License and Supply Agreement with Adalvo for Semaglutide injection	AQ
12/08/25	Lotus Pharmaceutical Achieves New First-Half Record in Revenue for 2025, While Q2 Impacted by FX and Timing of Lenalidomide Sales	AQ
22/02/25	Lotus announces FDA acceptance of Potential First-to-File ANDA Submission for Voclosporin soft gelatin capsules, a generic equivalent to Lupkynis	AQ
08/11/24	Lotus Achieves Second-Highest Quarterly Performance in Company History with 3Q24 Financial Results	AQ

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ELI LILLY AND COMPANY	+0.83%	+3.19%	+41.49%	+103.56%	1,051B
JOHNSON & JOHNSON	+1.93%	+2.11%	+37.08%	+65.09%	630B
ABBVIE INC.	+1.49%	+5.19%	+19.94%	+85.69%	489B
MERCK & CO., INC.	+2.26%	+0.90%	+69.32%	+40.53%	359B
ROCHE HOLDING AG	+1.45%	+3.50%	+23.29%	+41.62%	344B
NOVARTIS AG	+1.17%	+2.37%	+13.47%	+33.64%	272B
ASTRAZENECA PLC	+0.89%	+1.08%	-6.13%	+9.29%	246B
AMGEN INC.	+1.82%	+2.94%	+42.99%	+52.95%	224B
GILEAD SCIENCES, INC.	+2.77%	+4.44%	+29.01%	+98.99%	187B
Average	+1.62%	+2.53%	+30.05%	+59.04%	422.63B
Weighted average by Cap.	+1.47%	+2.44%	+33.36%	+69.01%

	2009	2010
Net sales	57.82M 51.64M 48.04M 43.7M 82.51M 5.6B 82.86M 578M 227M 2.85B 217M 212M 9.16B	72.7M 64.93M 60.4M 54.94M 104M 7.04B 104M 727M 285M 3.59B 273M 267M 11.51B
Net income	16.43M 14.68M 13.65M 12.42M 23.45M 1.59B 23.55M 164M 64.38M 811M 61.71M 60.36M 2.6B	14.42M 12.88M 11.98M 10.9M 20.58M 1.4B 20.67M 144M 56.52M 712M 54.17M 52.98M 2.28B
Net Debt	5.29 4.73 4.4 4 7.55 512.34 7.59 52.93 20.74 261.21 19.88 19.44 838.23	4.65 4.15 3.86 3.51 6.63 449.71 6.66 46.46 18.21 229.28 17.45 17.07 735.77

LOTUS PHARM Stock OTC Bulletin Board

Stocks

LTUS

US5457151042

Pharmaceuticals

Valuation: LOTUS PHARM

Latest news: LOTUS PHARM

Press Releases: LOTUS PHARM

Managers and Directors: LOTUS PHARM

Generic Pharmaceuticals

Financials

Company Profile